Navigation Links
Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
Date:8/24/2010

DALLAS and NEW YORK, Aug. 24 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced that its Director of Chemistry and Quality, Dr. Ric Zarzycki will give an invited presentation today on the Company's Cobalamin nanoparticle technology at a thought-leadership symposium being held at the American Chemical Society's ("ACS") 240th National Meeting & Exposition, at Boston Convention and Exhibition Center in Boston, Massachusetts, August 22-26, 2010.  The conference symposium titled, "Multifunctional Nanoparticles for Drug Delivery and Imaging", will focus on the advancement of nanotechnology in the pharmaceutical and diagnostic industries.  Dr. Zarzycki will highlight the distinct characteristics of Access' Cobalamin nanotechnology and the potential key role it will play in the future treatment of various diseases.  

"The ACS is a leading organization comprised of scientific thought-leaders from the US and from around the world and we are honored to be invited to present the significant progress made with our Cobalamin technology at a conference symposium which includes many leading nanotechnology scientists ," said Dr. Zarzycki, Director of Chemistry and Quality for Access Pharmaceuticals, Inc.  He continued, "The strong interest surrounding our Cobalamin nanotechnology and the distinct revolutionary benefits it lends to large-molecule formulations, especially the unprecedented oral bioavailability, remains encouraging as we continue development of novel formulations for various disease applications."

Last month, Access Pharmaceuticals announced its pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of a currently marketed, proprietary injectable drug, utilizing its proprietary Cobalamin Oral Drug Delivery Technology.  Although the name and the terms of the agreement have not been disclosed due to competitive reasons, management indicated that any successful formulation developed will be subject to a subsequent full-licensing agreement.

Cobalamin is Access' proprietary technology based upon the use of vitamin B12 for targeted delivery of drugs to disease sites and for oral drug delivery of drugs that otherwise have poor oral bioavailability. Access has focused its Cobalamin product development program on the oral delivery of insulin and human growth hormone, two peptides which currently can only be given by injection. Since presenting promising results at a major conference in mid-2008, Access has made substantial improvements to the formulation technology. A new Cobalamin-coated insulin-containing nanoparticle formulation delivered orally provided a pharmacological response (lowering of blood glucose levels in an animal model of diabetes) greater than 80% of that achieved by insulin delivered subcutaneously. This represents a substantial oral bioavailability, indicating that this formulation has potential for clinical development and ultimate commercialization. Adaptation of this technology has provided a Cobalamin human growth hormone formulation that has demonstrated good efficacy, represented by more than 25% improvement in weight gain, when given orally in an established animal model. Access continues to move both products towards clinical development.

About Access:Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase II clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.Contact: CompanyContact: Investor RelationsChristine BerniDonald C. Weinberger/Diana Bittner (media)Director of Investor RelationsWolfe Axelrod Weinberger Assoc. LLCAccess Pharmaceuticals, Inc.(212) 370-4500(212) 786-6208
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
2. Orchestrall Sponsors China Business Toolbox: Brings Focus to the How and When of China Market Access
3. DuPont Enhances its PROaccess℠ Business Strategy Through Acquisitions
4. Maximize Market Research to Improve Formulary Access Within Managed Markets Sector
5. Chinas first open-access journal Nano Research listed in Science Citation Index
6. Sudek of Tech Coast Angels Announces Networks Increased Commitment to Entrepreneurship and Innovation Through New Easy-Access Programs
7. Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe
8. Investor Relations Firm Access IR/PR and The Communications Strategy Group Announce Strategic Alliance
9. avVaa World Health Care Products Inc. Announces Access via Social Media Websites
10. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
11. Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Club. The event entitled “Stem Cells and Their Regenerative Powers,” was ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., ...
(Date:10/10/2017)... ... 2017 , ... The Pittcon Program Committee is pleased to ... who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each award ... conference and exposition for laboratory science, which will be held February 26-March 1, ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... line of medical marijuana products targeting the needs of consumers who are incorporating ... Kindred takes place in Phoenix, Arizona. , As operators of two successful Valley ...
Breaking Biology Technology:
(Date:6/30/2017)... Today, American Trucking Associations announced Seeing ... and eye tracking software, became the newest member ... "Artificial intelligence and advanced sensing algorithms ... driver,s attentiveness levels while on the road.  Drivers ... fatigue and prevent potential accidents, which could lead ...
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ( ... online age and identity verification solutions, announced today they ... Conference 2017, May 15 thru May 17, 2017, in ... and International Trade Center. Identity impacts ... and in today,s quickly evolving digital world, defining identity ...
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
Breaking Biology News(10 mins):